The civic record
Read. Follow. Verify.New Mexico SB 130 prohibits health insurers from charging copays for generic cholesterol drugs and coronary screenings
Last action · February 17, 2026: SHPAC: Reported by committee with Do Not Pass but with a Do Pass recommendation on Committee SubstitutionSponsor: Martin Hickey
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
New Mexico SB 130 prohibits health insurance policies, health maintenance organizations, and health care plans from imposing cost-sharing on generic cholesterol-lowering medications, under certain conditions, and s. The measure applies to health insurance policies delivered, issued for delivery, or renewed in the state on or after January 1, 2027.
- New Mexico Senate Bill 130 was considered during the 2026 Regular Session of the 57th Legislature. context
- Prior state statutes enacted in 2020 established baseline coverage requirements for heart artery calcium scans and cholesterol lipid panels in certain group health plans. context
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
health insurance policyholders
Insured residents receive coverage without cost-sharing for generic cholesterol medications and qualifying coronary artery calcium screenings under applicable plans.
health insurance carriers
Health insurers and health maintenance organizations must eliminate cost-sharing for generic cholesterol drugs and specific screenings for policies renewed on or after January 1, 2027.
Board of Pharmacy
The board receives new statutory duties to establish rules and protocols for cardiovascular risk assessment and lipid-lowering drug therapies.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Are high-deductible health plans subject to these rules immediately?
What tests are included in cholesterol lipid panels under the bill?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in Senate committee.
Procedural history
5 actions- Feb 17, 2026SenateSHPAC: Reported by committee with Do Not Pass but with a Do Pass recommendation on Committee Substitution
- Feb 15, 2026SenateCommitteeSent to committee - Referrals: SHPAC
- Feb 15, 2026SenateSTBTC ref w/drn
- Feb 11, 2026SenateSCC: Reported by committee to fall within the purview of a 30 day session
- Jan 23, 2026SenateCommitteeSent to SCC - Referrals: SCC/SHPAC/STBTC
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Expansion of Cardiovascular Preventive Mandates
The bill updates existing 2020 statutes regarding heart scans to broader coronary artery calcium screenings and adds explicit cost-sharing prohibitions for generic cholesterol and second-line step therapy drugs.
Connected Entities
Sources
www.nmlegis.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy45Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz25Current news / social attention level
Publisher tools